Propanc Biopharma, Inc. (PPCB): debt financing — Propanc Biopharma issues $82,500 promissory note to accredited investor

Propanc Biopharma, Inc.

Principal amount $82,500; purchase price $75,000; 10% annual interest.
Maturity date September 15, 2025; proceeds used for general working capital.
Repayment: 100% of principal if repaid by Aug 18, 2025; 120% if after Aug 18 up to Sept 18, 2025.
Note issued under private placement exemption Rule 506/Reg D; no equity securities sold.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

Propanc Biopharma, Inc. incurred convertible notes of $82,500 with an accredited investor at 10% per annum maturing September 15, 2025.

Instrument: convertible notes
Principal: $82,500
Counterparty: an accredited investor
Rate: 10% per annum
Maturity: September 15, 2025
Event: incurrence

Exact text from the filing

Effective July 18, 2025, Propanc Biopharma, Inc. (the “Company”) issued a Promissory Note to an accredited investor (the “Investor”) in the aggregate principal amount of 82,500 (the “Note”), for a purchase price of $75,000.

View on SEC.gov

10 debt financings filed in the last 30 days. Browse all debt financings →

Propanc Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-020574

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.